While there are several studies observing the benefit of KIR-mismatched NK cells in leukemias [29,30,31,32,33,34,35], more clinical and preclinical studies are needed to demonstrate the benefit of KIR mismatch in pediatric solid tumors. The gene discussed is KIR3DL1; the disease is leukemia.